Latest Healthcare It News

An independent in vivo study from the University of South Florida reveals ArtemiC™ significantly boosts survival and reduces inflammation in a severe viral model, reinforcing its promise as a novel immunomodulatory therapy.

Neuren Pharmaceuticals has initiated the first US investigational site for its pivotal Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, marking a significant milestone in addressing this rare neurodevelopmental disorder.

Genetic Signatures reported a 63% revenue increase to $15.9 million in FY25, alongside a 28% reduction in underlying losses and a strategic shift in its automated diagnostics platform development.

Genetic Signatures Limited reported a 63% revenue surge to $15.9 million in FY25, driven by strong Australian sales and progress in EMEA, while navigating a $20.1 million net loss and a strategic pivot towards partnerships for automated diagnostics.

LTR Pharma’s SPONTAN nasal spray has achieved unanimous patient satisfaction in treating erectile dysfunction after prostate surgery, signaling a promising shift in therapy preferences.

Regis Healthcare reported robust FY25 financial results, driven by increased occupancy, strategic acquisitions, and a strong balance sheet, positioning itself well ahead of the new Aged Care Act reforms.

Regis Healthcare has reported a robust FY25 financial performance, marked by significant profit growth and strategic acquisitions, positioning itself for ambitious expansion in Australia’s aged care sector.

Regis Healthcare delivered a robust FY25 performance with a 14.5% revenue increase and a dramatic turnaround to a $49 million net profit. The company is advancing growth through acquisitions and greenfield developments, positioning itself strongly ahead of upcoming sector reforms.

Vitura Health Limited has announced its third fully franked dividend of 0.2 cents per share following a profitable FY2025, reinforcing its unique position in the medicinal cannabis sector. Shareholders are invited to participate in a discounted Dividend Reinvestment Plan.

Vitura Health reported modest revenue growth but a robust 23.5% increase in EBITDA for FY2025, fueled by key acquisitions and expanding telehealth services. Despite margin pressures in medicinal cannabis, the company’s strategic reset under new leadership sets the stage for further growth.

Apiam Animal Health has entered a Process Deed granting Adamantem exclusivity to pursue a $0.88 per share acquisition proposal. The Independent Board Committee signals intent to recommend the deal, pending due diligence and shareholder approval.

Vitura Health reported a modest revenue increase to $124 million for FY2025, while net profit dipped 5.35% due to margin pressures and investment in new platforms. The company declared a fully franked dividend and highlighted growth in telehealth and medical services.